The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index, and 1 are not checked yet.
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Open accessAbstract
In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Activating mutations in PIK3CA can also contribute to resistance to anti-EGFR therapy in KRAS-WT CRC patients by persistent activation of the PI3K/AKT/mTOR signaling pathway [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“While PI3K pathway inhibitors as a monotherapy have not shown significant antitumor effects in treating CRC, their utility in combination therapy is actively being studied.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 2×
“…in both the cytoplasm and nucleus, including the Bcl2-associated agonist of cell death (BAD), forkhead box O (FOXO), glycogen synthase kinase 3 (GSK3), the Full Akt activity is achieved through phosphorylation at the Serine 473 residue in the C-terminal hydrophobic motif by mTORC2 [17].”
BackgroundAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 4×
“Compared with other PI3K pathway inhibitors, dual PI3K/mTOR inhibitors can inhibit all PI3K catalytic isoforms, mTORC1, and mTORC2 [80] and should block this pathway completely and overcome the feedback inhibition observed with mTORC1 inhibitors (i.e., rapamycin analogs).”
BackgroundInfluentialColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 5×
“The PI3K/Akt/mTOR pathway axis is critical for cell survival, proliferation, and growth, and it is one of the most frequently altered pathways in human cancer, making it a promising target for cancer therapy [9–12].”
BackgroundInfluentialAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“…pan-PI3K inhibitors such as MEN1611 [55], pictilisib (GDC-0941) [56–58], pi-laralisib (XL147) [59–61], sonolisib (PX-866) [62], and taselisib (GDC-0032) [63] have also been investigated in several phase 1 and II trials for CRC treatment (Table 2). mutated cancers I Withdrawn NCT01501604 The use…”
BackgroundDiagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Hemmings, B. A., & Restuccia, D. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011189 · Cited by 1,049
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · cited 1×
“Further investigation in clinical trials is required to determine the full potential of dual TORC1/2 inhibitors in CRC treatment.”
BackgroundBendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624 · cited 2×
“…phase I/II trial (NCT03711058) is currently underway to evaluate the effect of copanlisib and an anti-PD-1 antibody, nivolumab, in combination in relapsed or refractory solid tumors with expansions in mismatch-repair-proficient (MSS) CRC [54]. solid tumors I Completed NCT01363232 赵 [46] Other…”
BackgroundMutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 528
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · cited 1×
“Hence, modulation of PI3K signaling inhibition is required to improve the efficacy of therapeutics that target various signaling pathways, including RTK signaling, in CRC treatment [140].”
BackgroundSarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
Sparks, C. A., & Guertin, D. A. (2010) · Oncogene · doi:10.1038/onc.2010.139 · Cited by 299
Mehrotra, S., Languino, L. R., Raskett, C. M., Mercurio, A. M., Dohi, T., & Altieri, D. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.021 · Cited by 291
Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease
Burke, J. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.005 · Cited by 276 · cited 1×
“These transmembrane receptors do not bind or activate PI3K directly; they phosphorylate adaptor proteins such as insulin receptor substrates 1 and 2 (IRS1, IRS2), growth factor receptor-bound protein 2 (Grb2)-associated binder ½ (GAB1/2), and rat sarcoma virus (RAS) family members [13].”
BackgroundAlpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer
Zhang, L., Zhou, F., & ten Dijke, P. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.10.001 · Cited by 260
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Wang, H., Quah, S. Y., Dong, J. M., Manser, E., Tang, J. P., & Zeng, Q. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3598 · Cited by 258
Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 238
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
Bahrami, A., Khazaei, M., Hasanzadeh, M., ShahidSales, S., Joudi Mashhad, M., Farazestanian, M., Sadeghnia, H. R., Rezayi, M., Maftouh, M., Hassanian, S. M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25950 · Cited by 230
Rodon, J., Braña, I., Siu, L. L., De Jonge, M. J., Homji, N., Mills, D., Di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0082-9 · Cited by 186
mTOR pathway in colorectal cancer: an update
Francipane, M. G., & Lagasse, E. (2014) · Oncotarget · doi:10.18632/oncotarget.1548 · Cited by 182
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158
Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti, A., Piazzi, G., Alquati, C., & Ricciardiello, L. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.007 · Cited by 155 · cited 1×
“It has been reported that the inhibition of the Wnt/ β -catenin pathway is associated with the upregulation of the PI3K/AKT/mTORC1 pathway in CRC, and blocking the PI3K/AKT/mTORC1 pathway results in Wnt/ β -catenin signaling hyperactivation as a compensatory mechanism [135].”
BackgroundShapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147 · cited 1×
“The PIK3CA gene mutation has been shown to increase CRC cell survival and proliferation, leading to chemotherapy resistance and a poor prognosis [28].”
BackgroundDolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 143
Do, K. T., Speranza, G., Bishop, R. J., Khin, S. A., Rubinstein, L., Kinders, R. J., Datiles, M. B., Eugeni, M. A., Lam, M. H., Doyle, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0212-z · Cited by 139
Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 137
Molecular mechanisms of the PRL phosphatases
Ríos, P., Li, X., & Köhn, M. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08565.x · Cited by 128
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 127
Targeting PI3K in Cancer: Any Good News?
Martini, M., Ciraolo, E., Gulluni, F., & Hirsch, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00108 · Cited by 123
Bendell, J. C., Varghese, A. M., Hyman, D. M., Bauer, T. M., Pant, S., Callies, S., Lin, J., Martínez, R., Wickremsinhe, E. R., Fink, A. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3421 · Cited by 118
Bendell, J. C., Nemunaitis, J. J., Vukelja, S. J., Hagenstad, C. T., Campos, L. T., Hermann, R. C., Sportelli, P., Gardner, L. R., & Richards, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1980 · Cited by 111
Juric, D., Bono, J. S. D., LoRusso, P. M., Nemunaitis, J. J., Heath, E. I., Kwak, E. L., Macarulla, T. M., Geuna, E., Miguel, M. J. D., Patel, C. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2888 · Cited by 107
Bendell, J. C., Kurkjian, C. D., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., Shih, K. C., Thompson, D. S., Lane, C. M., Finney, L. H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0218-6 · Cited by 101
Tabernero, J. M., van Geel, R. M. J. M., Guren, T. K., Yaeger, R. D., Spreafico, A., Faris, J. E., Yoshino, T., Yamada, Y., Kim, T. W., Bendell, J. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3544 · Cited by 99
Papadopoulos, K. P., Tabernero, J. M., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J. M., Shi, W., Égile, C., Ruiz-Soto, R., Laird, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2403 · Cited by 99
Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98 · cited 1×
“However, a phase I (NCT01347866) combination study of gedatolisib and irinotecan showed limited activity in patients with advanced CRC [90].”
BackgroundSchram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0322-4 · Cited by 96
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90 · cited 1×
“…(MSS) CRC [54]. solid tumors I Completed NCT01363232 赵 [46] Other pan-PI3K inhibitors such as MEN1611 [55], pictilisib (GDC-0941) [56–58], pi-laralisib (XL147) [59–61], sonolisib (PX-866) [62], and taselisib (GDC-0032) [63] have also been investigated in several phase 1 and II…”
BackgroundBardia, A., Gounder, M. M., Rodon, J. A., Jankú, F., Lolkema, M. P., Stephenson, J., Bedard, P. L., Schüler, M., Sessa, C., LoRusso, P. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0297 · Cited by 89
Damodaran, S., Zhao, F., Deming, D. A., Mitchell, E. P., Wright, J. J., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01648 · Cited by 87
Espósito, A., Viale, G., & Curigliano, G. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0034 · Cited by 86
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82 · cited 1×
“In addition, activating mutations in BRAF and PIK3CA may be partially responsible for the failure of anti-EGFR therapy in KRAS-WT CRC patients [134].”
BackgroundGonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82
Agarwal, E., Chaudhuri, A., Leiphrakpam, P. D., Haferbier, K. L., Brattain, M. G., & Chowdhury, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-145 · Cited by 79
Self-citationNg, K., Tabernero, J. M., Hwang, J. J., Bajetta, E., Sharma, S., Prete, S. A. D., Arrowsmith, E. R., Ryan, D. P., Šedová, M., Jin, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0027 · Cited by 78
Altomare, I. P., Bendell, J. C., Bullock, K. E., Uronis, H. E., Morse, M. A., Hsu, S. D., Zafar, S. Y., Blobe, G. C., Pang, H., Honeycutt, W., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0078 · Cited by 74
Cohen, E. E. W., Wu, K., Hartford, C. M., Kocherginsky, M., Eaton, K. N., Zha, Y., Nallari, A., Maitland, M. L., Fox-Kay, K., Moshier, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0110 · Cited by 74
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
Zhu, Y.-F. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i28.3745 · Cited by 68
WICKI, A. N., Brown, N. F., Xyrafas, A., Bize, V., Hawle, H., Berardi, S., Cmiljanović, N., Cmiljanović, V., Stumm, M., Dimitrijević, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.012 · Cited by 68
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Foley, T. M., Payne, S. N., Pasch, C. A., Yueh, A. E., Hey, D. R. V. D., Korkos, D. P., Clipson, L. J., Maher, M. E., Matkowskyj, K. A., Newton, M. A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0256 · Cited by 64
Spindler, K. G., Mau‐Sørensen, M., Pallisgaard, N., Andersen, R. F., Havelund, B. M., Pløen, J., Lassen, U., & Jakobsen, A. K. M. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.776175 · Cited by 60
Tangled Webs: Evidence of Cross-Talk Between c-Raf-1 and Akt
Jun, T., Gjoerup, O. V., & Roberts, T. M. (1999) · Science Signaling · doi:10.1126/stke.1999.13.pe1 · Cited by 60
Li, C., Cui, J., Chen, M., Liu, C., Liu, F., Qian-de, Z., Zou, J., & Lu, P. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972274 · Cited by 56
McRee, A. J., Sanoff, H. K., Carlson, C. A., Ivanova, A., & O’Neil, B. H. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0298-3 · Cited by 54
Rodon, J. A., Fidalgo, J. A. P., Krop, I. E., Burris, H. A., Zotano, Á. G., Britten, C. D., Becerra, C., Schellens, J. H. M., Richards, D., Schüler, M., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3610-z · Cited by 54
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 50
Bendell, J. C., Jones, S. F., Hart, L. L., Spigel, D. R., Lane, C. M., Earwood, C., Infante, J. R., Barton, J. H., & Burris, H. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0177-3 · Cited by 47
Choudhury, A. D., Higano, C. S., Bono, J. S. D., Cook, N., Rathkopf, D. E., Wisinski, K. B., Martín-Liberal, J., Linch, M. D., Heath, E. I., Baird, R. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3087 · Cited by 47
Bendell, J. C., Ervin, T. J., Senzer, N. N., Richards, D., Firdaus, I., Lockhart, A. C., Cohn, A. L., Saleh, M. N., Gardner, L. R., Sportelli, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba3501 · Cited by 44
Wolpin, B. M., Ng, K., Zhu, A. X., Abrams, T. A., Enzinger, P. C., McCleary, N. J., Schrag, D., Kwak, E. L., Allen, J. N., Bhargava, P., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0378 · Cited by 43
Ezrin expression and cell survival regulation in colorectal cancer
Leiphrakpam, P. D., Rajput, A., Mathiesen, M. R., Agarwal, E., Lazenby, A. J., Are, C., Brattain, M. G., & Chowdhury, S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.014 · Cited by 43
Self-citationKrop, I. E., Jegede, O. A., Grilley‐Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00424 · Cited by 43
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
Doi, T., Fuse, N., Yoshino, T., Kojima, T., Bando, H., Miyamoto, H., Kaneko, M., Osada, M., & Ohtsu, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3198-0 · Cited by 42
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Hey, D. R. V. D., Depke, M. G., Korkos, D. P., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0510 · Cited by 40
Ganesan, P., Piha-Paul, S. A., Naing, A., Falchook, G. S., Wheler, J. J., Jankú, F., Zinner, R., Laday, S., Kies, M. S., & Tsimberidou, A. M. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0013-1 · Cited by 40
Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF4E/PUMA pathway
Wang, H., Liu, Y., Ding, J., Huang, Y., Liu, J. L., Liu, N., Ao, Y., Hong, Y., Wang, L., Zhang, L., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0117-7 · Cited by 38
Azaro, A., Massard, C., Tap, W. D., Cassier, P. A., Merchan, J. R., Italiano, A., Anderson, B., Yuen, E., Yu, D., Oakley, G. J., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01094-6 · Cited by 37
Bedard, P. L., Davies, M. A., Kopetz, S., Juric, D., Shapiro, G. I., Luke, J. J., Spreafico, A., Wu, B., Castell, C., Gomez, C., et al. (2017) · Cancer · doi:10.1002/cncr.31044 · Cited by 37
Shen, C., Tannenbaum, D., Horn, R. G., Rogers, J. E., Eng, C., Zhou, S., Johnson, B., Kopetz, S., Morris, V. K., Overman, M. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.13588 · Cited by 36
Gilcrease, G. W., Stenehjem, D. D., Wade, M. L., Weis, J. R., McGregor, K., Whisenant, J. R., Boucher, K. M., Thorne, K., Orgain, N., Garrido‐Laguna, I., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0645-2 · Cited by 33
Shapiro, G. I., LoRusso, P. M., Cho, D. C., Musib, L. C., Yan, Y., Wongchenko, M. J., Chang, I., Patel, P. H., Chan, I. T., Bohorquez, S. M. S., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00975-6 · Cited by 32
Wheler, J. J., Mutch, D. G., Lager, J. J., Castell, C., Liu, L., Jiang, J., & Traynor, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0257 · Cited by 30
Leong, S., Moss, R. A., Bowles, D. W., Ware, J. A., Zhou, J., Spoerke, J. M., Lackner, M. R., Shankar, G., Schutzman, J. L., van der Noll, R., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0090 · Cited by 30
Arkenau, H., Mateo, J., Lemech, C., Infante, J. R., Burris, H. A., Bang, Y., Eder, J. P., Herbst, R. S., Sharma, S., Chung, H. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2514 · Cited by 28
Revisiting mTOR inhibitors as anticancer agents
Teng, Q., Ashar, Y. V., Gupta, P., Gadee, E., Fan, Y., Reznik, S. E., Wurpel, J. N. D., & Chen, Z. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.030 · Cited by 28
Goodwin, R. A., Jonker, D. J., Chen, E. X., Kennecke, H. F., Cabanero, M., Tsao, M., Vickers, M. M., Bohemier, C., Lim, H. J., Ritter, H. D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00814-3 · Cited by 27
A phase I–II study on the combination of rapamycin and short course radiotherapy in rectal cancer
Buijsen, J., van den Bogaard, J., Jutten, B., Belgers, E. H. J., Sosef, M. N., Leijtens, J. W. A., Beets, G. L., Jansen, R. L. H., Riedl, R. G., Clarijs, R., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.07.039 · Cited by 26
Wu, Y.-L. L. C., ZHANG, L., Trandafir, L., Dong, T., Duval, V., Hazell, K., & Xu, B. (2016) · Anticancer Research · doi:10.21873/anticanres.11212 · Cited by 24
Leiphrakpam, P. D., Brattain, M. G., Black, J. D., & Wang, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001299 · Cited by 22
Self-citationEdelman, G. M., Rodon, J. A., Lager, J. J., Castell, C., Jiang, J., Allen, E. M. V., Wagle, N., Lindeman, N. I., Sholl, L. M., & Shapiro, G. I. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0691 · Cited by 20
Lin, A., Gu, T., Hu, X., Zhang, J., & Luo, P. (2022) · Journal of Immunology Research · doi:10.1155/2022/8179799 · Cited by 19
Wolff, R. A., Fuchs, M., Bartolomeo, M. D., Hossain, A. M., Stoffregen, C., Nicol, S. J., & Heinemann, V. (2011) · Cancer · doi:10.1002/cncr.26692 · Cited by 19
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 18
Self-citationPrognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer
Leiphrakpam, P. D., Lazenby, A. J., Chowdhury, S., Smith, L. M., Mathiesen, M. R., Brattain, M. G., Wang, J., Black, J. D., & Are, C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25805 · Cited by 17
Self-citationSpindler, K. G., Demuth, C., Sørensen, B. S., Johansen, J. S., Nielsen, D. L., Pallisgaard, N., Høgdall, E. V. S., Pfeiffer, P., & Jensen, B. V. (2018) · Tumor Biology · doi:10.1177/1010428318811207 · Cited by 16
Cruz, C., Schüler, M., Machiels, J., Hess, D., Paz-Ares, L. G., Awada, A. H., von Moos, R., Steeghs, N., Rodon, J. A., Mesmaeker, P. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.627 · Cited by 15
The role and therapeutic implications of PI3K signaling pathway in cancer
Leiphrakpam, P. D., Chowdhury, S., Wang, J., Black, J. D., & Are, C. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26296 · Cited by 14
Self-citationDasari, A. N., Overman, M. J., Fogelman, D. R., Kee, B. K., Menter, D. G., Raghav, K. P. S., Morris, V. K., Oh, J., Wu, J. Y., Jiang, Z.-Q., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3563 · Cited by 14
Chu, Q. S.-C., Mahipal, A., Schüler, M., de Braud, F., Dirix, L. Y., Rampersad, A., Zhou, J., Wu, Y., Kalambakas, S. A., & Wen, P. Y. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.5 · Cited by 13
Toyoda, M., Watanabe, K., Amagasaki, T., Natsume, K., Takeuchi, H., Quadt, C., Shirao, K., & Minami, H. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3725-2 · Cited by 13
Hecht, J. R., Reid, T. R., Garrett, C. R., Beck, J. T., Davidson, S. J., MacKenzie, M. J., Brandt, U., Rizvi, S., & Sharma, S. (2015) · PubMed · Cited by 13
Correlation of PRL3 expression with colorectal cancer progression
Leiphrakpam, P. D., Lazenby, A. J., Smith, L. M., Brattain, M. G., Black, J. D., Wang, J., & Are, C. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26253 · Cited by 12
Self-citationDumbrava, E. E. I., Burton, E. M., Subudhi, S. K., Milton, D. R., Aparicio, A. M., Yap, T. A., Naing, A., Corn, P. G., Pilie, P. G., Zurita, A. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.5052 · Cited by 12
Townsend, A. R., Tebbutt, N. C., Karapetis, C. S., Cooper, P., Singhal, N., Yeend, S., Pirc, L., Joshi, R., Hardingham, J. E., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3590 · Cited by 11
Jakubowski, C. D., Collins, N. B., Sugar, E. A., Berg, M., Cao, H., Giannakis, M., Jaffee, E. M., & Azad, N. S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps4114 · Cited by 10
Lim, A. R., Kim, B., Kim, J. H., Hyun, M. H., Park, K. H., Kim, Y. H., & Lee, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390452 · Cited by 10
The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.
Nusrat, M., Syed, M., Katkhuda, R., Parra, E. R., Wistuba, I. I., Kong, P., Koehne, A. L., Dasari, A. N., Overman, M. J., Menter, D. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.154 · Cited by 8
Rodon, J. A., Schüler, M., Machiels, J., Hess, D., Paz-Ares, L. G., Awada, A. H., von Moos, R., Steeghs, N., Cruz, C., Mesmaeker, P. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.621 · Cited by 7
Yokota, T., Bendell, J. C., LoRusso, P. M., Tsushima, T., Desai, V., Kenmotsu, H., Watanabe, J., Ono, A., Murugesan, B. G., Silva, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2536 · Cited by 6
Chiorean, E. G., Picus, J., Breen, T., Ansari, R., Harb, W. A., Burns, M., Spittler, A. J., & Loehrer, P. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3618 · Cited by 5
Capano, S., Merlino, G., Bigioni, M., Tunici, P., Cottino, F., Zanella, E. R., Vurchio, V., Bertotti, A., Trusolino, L., Laurent, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1008 · Cited by 3
Mutation profiling of TSC1 and TSC2 genes in solid tumors using comprehensive NGS panel.
Li, Y., Chen, R., Zhao, J., Zhu, L., Xu, J. H., Ma, F., Guo, R., Xu, C., Wang, W., Yi, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e24244 · Cited by 3
Baranda, J. C., Reed, G. A., Williamson, S. K., Perez, R. P., Stoltz, M., Mackay, C., Madan, R., Pessetto, Z. Y., & Godwin, A. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.655 · Cited by 2
Sharma, S., Chiorean, E. G., Alistar, A. T., Braiteh, F. S., Matrana, M. R., Becerra, C. R., Grigorian, B., Hou, S., Schmid, A. N., & Desai, N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e16050 · Cited by 1
Phase I clinical trial of lenalidomide with temsirolimus in patients with advanced cancer.
Ganesan, P., Piha-Paul, S. A., Naing, A., Falchook, G. S., Wheler, J. J., Jankú, F., Zinner, R., Laday, S., Kies, M. S., & Tsimberidou, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2604 · Cited by 1
Lim, A. R., Kim, B., Kim, J. H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3174557/v1 · Cited by 1
Cited by
PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment
Jiang, M., Zhang, K., Zhang, Z., Zeng, X., Huang, Z., Qin, P., Xie, Z., Cai, X., Ashrafizadeh, M., Tian, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70295 · Cited by 230
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
Research on the role and mechanism of the PI3K/Akt/mTOR signalling pathway in osteoporosis
Liu, C., Zhang, J., Ye, Z., Luo, J., Peng, B., & Wang, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1541714 · Cited by 76
Zhang, H., Tang, J., Cao, H., Wang, C., Shen, C., & Liu, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119007 · Cited by 27
Razzaq, S., Fatima, I., Moafian, Z., Rahdar, A., Fathi‐karkan, S., Kharaba, Z. J., Shirzad, M., Khan, S. A., & Pandey, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02670-z · Cited by 28
Metadata
- Authors
- Leiphrakpam, P., & Are, C.
- Affiliations
- University of Nebraska Medical Center (US)
- Corresponding author
- Leiphrakpam, Premila
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-09
- Volume
- 25
- Issue
- 6
- Pages
- 3178
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10970097
- OpenAlex
- W4392661434
- Cited by
- 193
- References
- 144
- Citations by year
- 2026: 82 · 2025: 82 · 2024: 29
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- colorectal cancer, PI3K/AKT/mTOR pathway, targeted therapy, drug resistance, tumor heterogeneity, metastasis, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.